MaxCyte, Inc. Forecasted to Post Q1 2025 Earnings of ($0.14) Per Share (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT) – Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of MaxCyte in a research report issued to clients and investors on Wednesday, May 8th. William Blair analyst M. Larew anticipates that the company will earn ($0.14) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for MaxCyte’s current full-year earnings is ($0.53) per share. William Blair also issued estimates for MaxCyte’s Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS and Q4 2025 earnings at ($0.13) EPS.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. The firm had revenue of $15.67 million for the quarter, compared to the consensus estimate of $15.60 million.

Several other equities analysts also recently weighed in on the company. BTIG Research cut their target price on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Stephens restated an “overweight” rating and issued a $11.00 target price on shares of MaxCyte in a report on Tuesday, April 23rd.

MaxCyte Price Performance

Shares of NASDAQ MXCT opened at $4.31 on Friday. MaxCyte has a 1-year low of $2.45 and a 1-year high of $5.55. The business’s 50 day moving average is $4.10 and its two-hundred day moving average is $4.37. The stock has a market capitalization of $450.58 million, a P/E ratio of -12.78 and a beta of 1.36.

Institutional Trading of MaxCyte

Several institutional investors and hedge funds have recently made changes to their positions in MXCT. Victory Capital Management Inc. grew its stake in MaxCyte by 23.0% in the 4th quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock worth $58,000 after acquiring an additional 2,306 shares in the last quarter. M&T Bank Corp boosted its position in MaxCyte by 3.4% during the 3rd quarter. M&T Bank Corp now owns 163,513 shares of the company’s stock valued at $510,000 after acquiring an additional 5,443 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of MaxCyte in the 4th quarter valued at $29,000. Russell Investments Group Ltd. bought a new position in shares of MaxCyte in the 1st quarter worth $28,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of MaxCyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock worth $83,000 after purchasing an additional 7,898 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.